These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 15516258

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients.
    Csapo Z, Benavides-Viveros C, Podder H, Pollard V, Kahan BD.
    Transplant Proc; 2005 Jun; 37(5):2032-6. PubMed ID: 15964331
    [Abstract] [Full Text] [Related]

  • 3. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET.
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
    Zhang PL, Malek SK, Blasick TM, Pennington JR, Masker KK, Lun M, Potdar S.
    Ann Clin Lab Sci; 2007 Sep; 37(2):121-6. PubMed ID: 17522366
    [Abstract] [Full Text] [Related]

  • 6. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
    Basu A, Ramkumar M, Tan HP, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.
    Transplant Proc; 2005 Mar; 37(2):923-6. PubMed ID: 15848576
    [Abstract] [Full Text] [Related]

  • 7. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, Toit C, Abrahams L, Thomas V, Bunjes D, Duncker C, Wiesneth M, Selleslag D, Hidajat M, Starobinski M, Bird P, Waldmann H.
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.
    Transplant Proc; 2011 Jul; 43(6):2365-78. PubMed ID: 21839271
    [Abstract] [Full Text] [Related]

  • 15. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
    Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, Mulligan DC, Moss AA, Mekeel KL, Reddy KS.
    Clin Transpl; 2009 Jul; ():407-14. PubMed ID: 20524306
    [No Abstract] [Full Text] [Related]

  • 16. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J, Bono MR, Fierro A, Iñiguez R, Zehnder C, Rosemblatt M, Calabran L, Herzog C, Benavente D, Aguiló J, Pefaur J, Alba A, Ferrario M, Simon W, Contreras L, Buckel E.
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [Abstract] [Full Text] [Related]

  • 17. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
    Baez Y, Giron F, Niño-Murcia A, Rodríguez J, Salcedo S.
    Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
    [Abstract] [Full Text] [Related]

  • 18. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
    Hale G, Waldmann H.
    Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation.
    Ona ET, Danguilan RA, Africa J, Cabanayan-Casasola CB, Antonio ZL, Gutierrez-Marbella MA, dela Cruz R, Bumanglag N, Espedilla ME.
    Transplant Proc; 2008 Sep; 40(7):2226-9. PubMed ID: 18790199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.